Stockwinners Market Radar for November 06, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:08 EDT Matador sees FY17 oil production 7.7M-7.75M barrels - Sees FY17 adjusted EBITDA $300M-310M. Sees FY17 drilling and completions CapEx $440M-$465M.

19:02 EDT Cellectis: FDA lifts clinical hold on Phase 1 clinical trials with UCART123 - Cellectis announced that the U.S. Food and Drug Administration has lifted the clinical hold, previously announced on September 4, 2017, on Phase 1 trials of Cellectis' UCART123 product candidate in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Cellectis agreed with the FDA to the following main revisions to be implemented in Phase 1 UCART123 protocols to lift the hold: Decrease of the cohort dose level to 6.25x104 UCART123 cells/kg; Decrease of the cyclophosphamide dose of the lympho-depleting regimen to 750 mg/m/day over three days with a maximum daily dose of 1.33 grams of cyclophosphamide; Inclusion of specific criteria at Day 0, the day of UCART123 infusion, such as no new uncontrolled infection after receipt of lymphodepletion, afebrile, off all but replacement dose of corticosteroids, no organ dysfunction since eligibility screening; Provision to ensure that the next three patients to be treated in each protocol will be under the age of 65; Provision to ensure that the enrollment will be staggered across the UCART123 protocols AML123 and ABC123: at least 28 days should elapse between the enrollments of two patients across the two studies. Cellectis is currently working with the investigators and clinical sites to obtain IRB's approval on the revised protocols and resume patient enrollment.

18:31 EDT Nabors Industries and Tesco receive antitrust clearance in U.S. and Canda - Nabors Industries (NBR) and Tesco (TESO), jointly provided a status update of the previously announced acquisition of Tesco Corporation by Nabors Industries. The two companies have recently received anti-trust clearance from the U.S. Department of Justice and the Canada Competition Bureau. In addition, the approval process with the Federal Antimonopoly Service of the Russian Federation was initiated, with its determination expected in the next few weeks. The companies further stated that a joint integration team has been working since early September to plan the integration of Tesco and Nabors and assure rapid realization of the anticipated synergies. The team remains committed to yielding the transaction synergies estimated at the time of the announcement.

18:08 EDT Playa Hotels & Resorts sees FY17 adjusted EBITDA $168M-$170M

18:01 EDT AlarmForce to be acquired by BCE for $16.00 per share in cash

17:52 EDT Resolute Energy sees FY17 general and administrative expenses $3.12 per Boe - Resolute's FY17 guidance range has been narrowed with respect to production to 24,500 to 25,500 Boe per day, which accounts for the full year impact of the Aneth Field sale and the Bronco activities. The company said "During the Q3 we experienced a modest shift in our oil percentage resulting from our mix of producing wells. Of the seven wells turned to production, four of them were in our Bronco and Mustang areas where we have higher initial gas to oil ratios. Based on our mix of producing wells and the sale of Aneth Field, which is 99 percent oil, we expect that our 2017 oil percentage will be between 60%-62%. Lease operating costs are currently expected to be $78M-$82M or $8.75 per Boe at the midpoint of the respective ranges. This represents an approximate seventeen percent reduction in per unit lease operating expense from the midpoint of our prior guidance. Currently we expect cash-based general and administrative expenses to be $28M-$29M, or $3.12 per Boe at the midpoint of our updated production and G&A guidance ranges, compared to $2.85 per Boe at the midpoint of our prior guidance ranges. We now expect total capital for the year to be $290M-$305M."

17:47 EDT Engine Capital raises stake in Hill International to 7.4% from 4.3% - Hill International is currently trading at an enterprise value to revenue of approximately 0.6x and an enterprise value to normalized EBITDA (assuming an EBITDA margin of 10%) of around 6.0x. Engine Capital believes that peer companies trade for at least 1x revenue and 9x EBITDA implying significant upside for the company's shares. Engine Capital expects that this valuation gap will close as the company demonstrates improved profitability and shows progress on its publicly-announced profit improvement plan. Engine Capital intends to continue to have discussions with the company's Board of Directors regarding various opportunities to increase and maximize shareholder value.

17:33 EDT On The Fly: After Hours Movers - UP AFTER EARNINGS: NeoPhotonics (NPTN), up 13.7%... Weight Watchers (WTW), up 10.1%... Lannett (LCI), up 8.5%. ALSO HIGHER: AmTrust (AFSI), up 3.7% after it agreed to transfer a 51% equity interest of its fee business to MDP... Salesforce (CRM), up 2.3% after it formed a new strategic partnership with Google (GOOG) and initiated fiscal 2019 revenue guidance... Las Vegas Sands (LVS), up 1.1% after its stock was upgraded to Overweight from Equal Weight at Morgan Stanley. DOWN AFTER EARNINGS: Teligent (TLGT), down 35.2%... TrueCar (TRUE), down 26.6%... Quantenna (QTNA), down 26%... Red Robin (RRGB), down 21%... Veritone (VERI), down 11.4%... Avis Budget (CAR), down 11.9%... Priceline (PCLN), down 10.1%... Nevro (NVRO), down 8.2%... TripAdvisor (TRIP), down 8.2%... Invitae (NVTA), down 7.7%... AMC Entertainment (AMC), down 6.6%... Skyworks (SWKS), down 5.3%... Tenet Healthcare (THC), down 5.1%... Zayo Group (ZAYO), down 3.1%... GoDaddy (GDDY), down 3%. ALSO LOWER: Hertz (HTZ), down 7.5% after Avis Budget reported weaker than expected guidance for fiscal 2017.

17:32 EDT EMC Insurance raises quarterly dividend to 22c from 21c - Dividend payable November 27, 2017, to stockholders of record as of November 20, 2017.

17:27 EDT Kraft Heinz to restate certain financials - In a regulatory filing, Kraft Heinz stated in part, "On October 31, 2017, the Audit Committee of the Board of Directors of The Kraft Heinz Company, after considering the recommendations of management and consulting with PricewaterhouseCoopers LLP, our independent registered public accounting firm, concluded that our condensed consolidated financial statements included in the quarterly reports on Form 10-Q for the quarterly periods ended April 1, 2017 and July 1, 2017 should not be relied upon due to the misstatement in adopting new Accounting Standards Update 2016-15. Shortly following the filing of this Current Report on Form 8-K, we will file amendments to our Quarterly Reports on Form 10-Q for the quarterly periods ended April 1, 2017 and July 1, 2017 to restate the previously issued interim financial statements in the Initial Filings to correctly classify certain items in our condensed consolidated statements of cash flows. The financial statements for the quarterly periods ended April 1, 2017, July 1, 2017, April 3, 2016 and July 3, 2016 included in the Amended Filings may be relied upon, as the misstatements described below will be corrected. We believe it is important that investors understand that these changes: were caused by a misapplication of ASU 2016-15; do not reflect a fundamental change in our underlying business; do not impact any other components of our consolidated financial statements, including, without limitation, cash and cash equivalents, net income, net sales or any other financial data (including non-GAAP financial measures, including Adjusted EBITDA or Adjusted EPS) that we had previously presented in our periodic reports or earnings releases (including in our earnings releases for the first, second and third quarters of 2017); and do not impact our compliance with our contractual obligations."

17:10 EDT U.S. Silica announces new $100M share repurchase

17:10 EDT U.S. Silica sees FY17 CapEx view at the high end of prior forecast or $375M

17:07 EDT Supernus raises FY17 net product sales $290M-$295M from $280M-$290M - Raises FY17 operating income view to $85M-$90M from $82M-$87M. Sees FY17 research and development expense of approximately $55M.

17:05 EDT CryoLife announces enrollment of first BioGlue trial patients in China - CryoLife announced that enrollment has started in the company's BioGlue clinical trial in China. The results from the trial will serve as the basis of the company's regulatory submission to the Chinese Food and Drug Administration to gain approval to commercialize BioGlue in China. Patients are currently being enrolled at multiple heart centers in China. "The initiation of patient enrollment in our BioGlue China clinical trial is a positive milestone that supports our effort to expand our global presence in key markets," stated Pat Mackin, CryoLife Chairman, President, and Chief Executive Officer. "We estimate there are more than 40,000 aortic surgeries in China each year, which represents a significant growth opportunity for BioGlue. We anticipate trial enrollment and follow up will take about one year, which would put us on track for potential CFDA approval of BioGlue by the end of 2019."

17:03 EDT Belmond sees FY17 RevPAR on constant basis 0%-2% - Sees Q4 RevPAR on a constant currency basis 3%-7%

17:00 EDT Weight Watchers up 10% to $49.26 after beat and raise quarter

16:55 EDT MPM Oncology Impact reports 12.5% passive stake in Sunesis

16:49 EDT GoDaddy reports Q3 total bookings $668M, up 25% y/y - Or 24.7% on a constant currency basis. Customers were 17.1M at quarter end, up 17.7% year over year, including the contribution from HEG.

16:46 EDT RSP Permian sees FY17 average daily production 53,000Boe/d-57,000Boe/d

16:45 EDT Asur reports October traffic down 4.2% - Grupo Aeroportuario del Sureste, S.A.B. de C.V. announced that total passenger traffic for October 2017 declined 4.2% when compared to October 2016. Passenger traffic rose 5.2% in Mexico, and declined 24.5% in San Juan and 13.0% in Colombia.

16:45 EDT Manitex trading resumes

16:41 EDT 1st Constitution Bancorp to acquire New Jersey Community Bank for $7.6M - 1ST Constitution Bancorp and New Jersey Community Bank jointly announced today that they have entered into a definitive agreement and plan of merger pursuant to which 1ST Constitution Bancorp will acquire New Jersey Community Bank in a stock and cash transaction valued at approximately $4.00 per share, or approximately $7.6 million in total consideration. Upon the closing of the transaction, New Jersey Community Bank will merge with and into 1ST Constitution Bank. The merger has been unanimously approved by the boards of directors of both institutions, and is anticipated to be completed at the end of the first quarter of 2018. Under the terms of the merger agreement, New Jersey Community Bank shareholders will receive $1.60 in cash and 0.1333 shares of 1ST Constitution Bancorp common stock, subject to adjustment as set forth in the merger agreement, for each share of New Jersey Community Bank common stock that they own. 1ST Constitution Bancorp expects to issue approximately 254,392 new shares of common stock in this transaction. This deal value equates to approximately 82% of New Jersey Community Bank's tangible book value as of September 30, 2017, and is anticipated to be accretive to 1ST Constitution Bancorp's earnings per share and tangible book value in 2018.

16:41 EDT Eminence Capital reports 6% passive stake in Ellie Mae

16:38 EDT Etsy reports 1.891M active sellers in Q3, up 10.8% y/y - Reports 31.68M active buyers in Q3, up 16.7% y/y.

16:34 EDT Etsy reports Q3 GMS $766.4M - "GMS was $766.4 million, up 13.2%, compared with the third quarter of 2016. We accelerated GMS growth by 140 bps compared with the second quarter of 2017, following several successful launches of new features and tools. Growth in GMS was also supported by 10.8% year-over-year growth in active sellers and 16.7% year-over-year growth in active buyers. Continuing the trend we've seen for multiple quarters, mobile visits once again grew faster than desktop visits. Percent mobile visits was approximately 67% compared with approximately 65% in the third quarter of 2016. Percent mobile GMS was approximately 52% compared with approximately 49% in the third quarter of 2016 and approximately 51% in the second quarter of 2017. Mobile web continued to be the largest driver of both overall visit growth and mobile GMS growth. Mobile web visits were approximately 47% of overall visits and mobile app and mobile web GMS each grew significantly faster than desktop GMS during the third quarter. Percent international GMS was approximately 34% in the third quarter of 2017, up from approximately 30% in the third quarter of 2016, and up from approximately 32% in the second quarter of 2017. Net international GMS growth accelerated to approximately 25% year-over-year and grew faster than overall GMS during the third quarter for the sixth consecutive quarter. GMS between international buyers and sellers in the same country grew 54% year-over-year during the third quarter demonstrating our continued progress in building and deepening local Etsy communities around the world."

16:32 EDT AnaptysBio announces 'positive' top-line results for Phase 1 trial of ANB019 - AnaptysBio announced positive top-line results from an interim analysis of an ongoing single and multiple ascending dose Phase 1 trial of ANB019, its investigational anti-interleukin-36 receptor therapeutic antibody, in healthy volunteers. Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties that support advancement of ANB019 into patient Phase 2 studies. ANB019 was well-tolerated by all subjects and no dose-limiting toxicities were observed to date. No serious adverse events were reported among the single ascending dose cohorts through completion of monitoring, and none have been observed in the multiple ascending dose cohorts to date.

16:28 EDT Callon Petroleum sees FY17 total production 24,000BOE/d-25,500BOE/d - Sees FY17 % of oil 77%.

16:26 EDT ILG subsidiary extends exclusive affiliation agreement with Accor Vacation Club - Interval International, a leading global provider of vacation services and an operating business of ILG announced the renewal of its master affiliation agreement with APVC, operator of Accor Vacation Club. The multi-year contract extends the relationship first established in 2000 and comprises the existing 23 club properties, as well as future properties that become part of Accor Vacation Club. As part of the agreement, Interval is providing a comprehensive package of customized services, including points-based exchange. New members who purchase at Accor Vacation Club will be enrolled as individual members of Interval International and will also become Interval Gold members, entitling them to a number of flexible exchange opportunities and upgraded benefits and services.

16:25 EDT Diplomat Pharmacy CEO: 2017 is a transition year for Diplomat - Phil Hagerman, CEO and Chairman of Diplomat, commented "Diplomat's third quarter results were solid as we achieved financial results in-line with our expectations, experienced continued growth in our oncology and infusion businesses and expansion in our access to limited distribution drugs, as well as encouraging trends within the specialty pharmacy industry. I am pleased to announce we have resolved our arbitration with CVS and have transitioned from a PSAO contract to a direct contract with CVS, one of the nation's largest health care companies. 2017 is a transition year for Diplomat, and we continue to make significant strides, including broadening our services through our acquisitions of NPS and 8th Day Software and enhancing our senior management team to execute on our strategy to become a broader-based health care company."

16:24 EDT Diplomat Pharmacy narrows FY17 adj EBITDA view to $99M-$102M from $97M-$103M

16:22 EDT Presidio CEO 'confident' in ability to achieve FY18 outlook - Presidio CEO Bob Cagnazzi said, "We are encouraged by our strong start to the year, and we are confident in our ability to achieve our outlook for Fiscal 2018, which includes: Total Revenue growth of approximately 5.5%; Adjusted EBITDA margin in the low 8% range; and Pro Forma Diluted EPS growth in the high single digit range. In addition, we expect to finish Fiscal 2018 with our net total leverage ratio in the mid-2x range, excluding any material strategic acquisitions. We continue to execute against our strategic growth initiatives to deliver earnings growth, margins ahead of our peers, and consistent deleveraging to drive shareholder value creation."

16:20 EDT Quantenna down 5.85% after reporting Q3 results, giving Q4 guidance

16:18 EDT McKesson to acquire RxCrossroads from CVS in $735M deal - McKesson (MCK) announced that it has signed a definitive agreement to purchase RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health Corporation (CVS). The transaction is valued at $735M, or approximately $635M net of the present value of incremental cash tax benefits, and will be funded by cash on hand. The acquisition is expected to close in the fourth quarter of Fiscal 2018, subject to customary closing conditions, including necessary regulatory clearances. This acquisition will enhance McKesson's existing commercialization solutions for manufacturers of branded, specialty, generic and biosimilar drugs, including comprehensive patient support ("hub") services, custom pharmacy solutions and third-party logistics, allowing McKesson to grow its end-to-end offerings for manufacturers. In addition, the acquisition will add plasma logistics to McKesson's manufacturer services, complementing the company's established customer-facing plasma offerings. Following the close of the transaction, RxCrossroads will become part of the company's McKesson Specialty Health business. McKesson expects the impact of this transaction to be approximately 20c accretive to adjusted earnings per diluted share by the third year following the close of the transaction.

16:17 EDT DiamondRock reports Q3 RevPAR $195.13, a 2.1% increase from last year -

16:13 EDT Salesforce, Google form new strategic partnership - Salesforce (CRM) and Google (GOOG, GOOGL) announced a new strategic partnership to enable smarter, more collaborative experiences for customers. As part of the agreement, Salesforce has named Google Cloud as a preferred public cloud provider to support the company's rapidly growing global customer base. Salesforce plans to use Google Cloud Platform for its core services as part of the company's international infrastructure expansion. In addition, the companies will offer new integrations that connect Salesforce, the world's #1 CRM platform, with G Suite, Google's transformative productivity and team collaboration services, enabling customers to surface powerful customer intelligence seamlessly between Salesforce Lightning and Quip and Gmail, Hangouts Meet, Google Calendar, Drive, Docs and Sheets. To enable Salesforce's more than 150,000 customers to quickly and easily realize the productivity gains made possible by bringing together these solutions, eligible Salesforce customers that are new to Google's growing productivity and collaboration services will be able to use G Suite at no charge for up to one year. The companies will also deeply integrate Salesforce with Google Analytics, seamlessly connecting sales, marketing and advertising data across Salesforce Sales Cloud, Salesforce Marketing Cloud and Google Analytics 360, for the first time. Customers will be able to gain new consumer insights so they can deliver the most relevant experience at the right moment-whether that's talking to a sales person, opening an email, visiting a website, clicking an ad, or searching on Google. In addition, as part of the agreement, Google will continue to use Salesforce as its preferred CRM provider to engage with its cloud customers in new and meaningful ways, while Salesforce will continue to use G Suite as its preferred email and productivity provider.

16:11 EDT GoDaddy raises FY17 unlevered free cash flow view to about $485M - Representing 36% growth versus the approximately $357M in unlevered free cash flow generated in 2016.

16:09 EDT Plains All American still sees FY17 adjusted EBITDA $2.075B

16:06 EDT Priceline CEO says growth, operating results 'solid' in seasonally busy Q3 - "The Priceline Group delivered solid growth and operating results during our seasonally busy third quarter. Globally, our accommodation business booked 178 million room nights in the third quarter, up 19% over the same period last year. Booking.com showed continued momentum with approximately 1.5 million properties on its platform, up 41% over last year. This represents 26.9 million potentially bookable rooms, which we believe to be the largest, and most diverse, selection of instantly bookable accommodations in the world. As we look to the fourth quarter and beyond, we will continue to focus on making the right investments across our brands - in people, systems, and marketing - to continue to grow our business for the long term," said CEO Glenn Fogel.

16:05 EDT Diamondback Energy ups FY17 production view to 77.5-78.5MBOE/d from 74-78MBOE/d

16:02 EDT Kimco Realty begins construction on The Boulevard - Kimco Realty Corp. has commenced construction on The Boulevard, the company's dramatic $186M redevelopment of the former Hylan Plaza shopping center on Staten Island, New York. The dynamic retailer lineup for this grocery-anchored Kimco Signature Series redevelopment includes best-in-class brands such as ShopRite, Alamo Drafthouse, Marshalls, Ulta, PetSmart and LA Fitness. The 460,000-square-foot open-air center, which will feature a multi-level "main street" format, is scheduled to open in early 2020.

15:59 EDT QuintilesIMS to change name to IQVIA, symbol to 'IQV' - QuintilesIMS (Q) announced that it will be changing its name to IQVIA, effective November 6. Beginning on November 15, equity shares of the company will trade on the NYSE under the new name and new ticker symbol "IQV." Until then, IQVIA will continue to be listed under QuintilesIMS and symbol "Q" per the listing notification requirements of the NYSE.

15:43 EDT James E. Flynn reports 8.28% passive stake in Lannett

14:01 EDT Samsung's VP of Immersive Nick DiCarlo leaves company - Nick DiCarlo, Samsung's VP of immersive products strategy and product marketing, has left the company, DiCarlo tweeted on Friday. "It was a very fulfilling 10yrs, and I continue to be a big believer in immersive tech like VR & AR," he said. Reference Link

13:57 EDT Royale Energy: Proxy firms recommend investors vote for Matrix Oil merger - Royale Energy announced that Institutional Shareholder Services and Glass, Lewis & Co., have both recommended that Royale shareholders vote "FOR" the proposed merger with Matrix Oil Management as described in the joint proxy statement/prospectus for the annual meeting of its shareholders to be held on Thursday, November 16. In its report, ISS stated, among other things, that "The transaction will considerably increase the company's scale for oil production and is anticipated to place the company back in compliance for NASDAQ listing requirements. Furthermore, initial reaction to both the letter of intent and definitive agreement announcements were markedly positive. On balance, therefore, support for this proposal is warranted." Additionally, Glass Lewis concluded that the merger warrants shareholder support and recommends that shareholders vote FOR the proposal.

13:41 EDT Netflix ticks lower after CNBC report of Disney, 21st Century Fox talks - Shares of Netflix (NFLX) moved lower after CNBC reported that Disney (DIS) held talks to acquire most of 21st Century Fox (FOXA). Shares of Netflix remain up 22c to $200.20 in afternoon trading.

13:31 EDT 21st Century Fox trading halted, volatility trading pause

13:01 EDT Insteel acquires assets of Ortiz Engineered Products, terms not disclosed - Insteel Industries announced that its wholly owned subsidiary, Insteel Wire Products, has acquired certain of the assets of Ortiz Engineered Products. The terms of the transaction were not disclosed. OEP provides value-engineered reinforcing solutions for the concrete construction industry, converting projects that are designed with conventional rebar to welded wire reinforcement.

12:57 EDT Siemens Gamesa announces restructuring plan, will affect 6,000 employees - Siemens Gamesa, a joint venture of Siemens (SIEGY) and Gamesa (GCTAF), announced restructuring plan affecting a maximum of 6,000 employees located in 24 countries. Discussions with employee representatives will start immediately, in accordance with applicable rules and regulations in each country. Information on the final agreements will be communicated in due course, once negotiations are completed. "This plan, which will be implemented in the coming months, is a necessary step to strengthen the group and consolidate its position as a market leader," the company said. The previously announced synergy target of EUR230M is confirmed as a minimum and the company expects to achieve this target in the third year, 12 months ahead of schedule.

12:36 EDT Wells Fargo signs data exchange deals with Expensify, PointServ - Wells Fargo announced agreements with Expensify and PointServe as part of its efforts to reshape the data-exchange models it uses when sharing customer information with third-party services. San Francisco-based Expensify provides automated solutions for business expense reporting and receipt management. PointServ, based in Burlingame, Calif., offers solutions that enable mortgage lenders, bankers, and financial institutions to process loan applications more efficiently by gathering directly from the source the documents applicants need for loan decisioning. The Expensify agreement will make it easier for Wells Fargo credit-card holders who use Expensify to document and report monthly business expenses. When collecting data for monthly reporting, Wells Fargo and Expensify will use an application programming interface to share the data securely. Under the PointServ agreement, when a Wells Fargo customer applies for a real estate loan with a mortgage company that uses PointServ solutions to gather the financial documents it needs to make a loan decision, a Wells Fargo API will deliver customer statements and bank account activity to PointServ.

12:32 EDT Ackman, in final public comment on Herbalife, says investment will work out - Pershing Square's Bill Ackman, while speaking on CNBC, says he's been right on the facts about Herbalife even though the shares have gone from $48 to $66. The company has retired around 30% of the shares while Carl Icahn also amassed a stake, Ackman says. The company has levered up to buy back shares, and fundamentals "will rule at the end of the day," Ackman proclaims. The investor noted that he can no longer be forced to cover his short position as his stake is now entirely in puts. Ackman, while announcing today will be the last time he speaks about Herbalife publicly, said the stake will ultimately "turn into a nice investment." The nutrition company is down 2% to $66.75 in midday trading.

12:21 EDT Analysts cut Qualcomm rating after rally on Broadcom bid news - Wells Fargo and Standpoint Research both downgraded Qualcomm (QCOM) to neutral-equivalent rating, citing the stock's rally following Broadcom's (AVGO) unsolicited takeover offer of $70 per share. According to media reports, Broadcom is preparing for a proxy battle should Qualcomm reject the company's takeover bid. TAKEOVER OFFER: Broadcom has announced a proposal to acquire all of the outstanding shares of Qualcomm for per share consideration of $70.00 in cash and stock. Under Broadcom's proposal, the $70 per share to be received by Qualcomm stockholders would consist of $60 in cash and $10 per share in Broadcom shares. The Broadcom proposal stands whether Qualcomm's pending acquisition of NXP Semiconductors (NXPI) is consummated on the currently disclosed terms of $110 per NXP share or the transaction is terminated. The proposed transaction is valued at approximately $130B on a pro forma basis, including $25B of net debt, giving effect to Qualcomm's pending acquisition of NXP on its currently disclosed terms. According to media reports, Broadcom is preparing for a proxy battle should Qualcomm reject its unsolicited takeover offer. CNBC's David Faber has said, citing sources, that the latter is resistant to the bid, though the company has only publicly acknowledge so far that it received and will review the offer. MOVING TO THE SIDELINES: In a research note to investors, Wells Fargo analyst David Wong downgraded Qualcomm to Market Perform from Outperform amid the rally in shares following Broadcom's unsolicited takeover offer. Going forward Qualcomm will not trade on fundamentals but on developments regarding the acquisition offer, Wong argued. Further, the analyst pointed out that he believes Broadcom's offer price assigns essentially no incremental value to Qualcomm's stock associated with the possible closing of the NXP Semiconductors deal or resolution of outstanding disputes. Meanwhile, his peer at Standpoint Research also cut Qualcomm's rating to Hold from Buy. Analyst Ronnie Moas cited the rally in the shares since news broke of Broadcom's acquisition offer. WHAT'S NOTABLE: Commenting on the news this morning, Oppenheimer analyst Rick Schafer applauded the potential acquisition of Qualcomm by Broadcom as he sees obvious financial/strategic merit in combining the leading back-end handset supplier with Broadcom's leading front-end portfolio. The analyst also told investors that he thinks a deal fits squarely into the latter's playbook of acquiring companies trading at below-peer multiples with dominant market share, heavy customer/product concentration, and obvious cost synergies. Schafer added that he remains a long-term buyer of Broadcom, reiterating an Outperform rating on the shares. In a research note of his own, KeyBanc analyst John Vinh voiced a similar opinion, saying he believes this deal would make sense as he sees significant cost synergies and the opportunity for Broadcom to leverage its healthy relationship with Apple (AAPL) to mend the current strife between Qualcomm and the iPhone maker. Additionally, Vinh noted that the deal should be meaningfully accretive to Broadcom and could drive consolidated EPS of $22.97. In his M&A scenario analysis, the analyst is assuming Qualcomm backs out of its bid for NXP Semiconductors and Broadcom looks to divest QTL and closes on its acquisition of Brocade (BRCD). In terms of implications, Vinh told investors the he views it as positive for Cavium's (CAVM) ThunderX business. PRICE ACTION: In early afternoon trading, shares of Broadcom have dropped about 1% to $271.62, while Qualcomm's stock has gained over 1.5% to $62.77. Over the last five sessions, Qualcomm shares are up about 15%.

12:08 EDT Tivity Health slides after UnitedHealth adds new fitness benefit to MA plans - Shares of Tivity Health (TVTY) are sharply lower in midday trading, which is being attributed to UnitedHealth (UNH) announcing a new fitness benefit for certain members of its Medicare Advantage plans. Tivity Health operates the SilverSneakers, Prime Fitness and WholeHealth Living networks. The SilverSneakers senior fitness program is offered to members of Medicare Advantage, Medicare Supplement, and Group Retiree plans. Tivity is down 31.5% to $32.90 near noon following UnitedHealth's announcement.

12:02 EDT Ackman doesn't know if Pershing will win ADP proxy - Pershing Square's Bill Ackman says he doesn't know if he'll win tomorrow's proxy contest against ADP and is "puzzled" by David Faber's report that a loss is all but expected. Ackman is speaking on CNBC.

11:32 EDT Intel, AMD team-up on PC chips to challenge Nvidia - Intel (INTC) and Advanced Micro Devices (AMD) are partnering for a computer chip that combines the former's processor with the latter's graphics unit in an effort to compete with Nvidia (NVDA), the leader in graphics chips. Separately, and ahead of quarterly results later this week, Morgan Stanley analyst Joseph Moore raised his price target on Nvidia to $210. INTEL, AMD PARTNERSHIP: Christopher Walker, VP of the Client Computing Group and general manager of the Mobile Client Platform at Intel, stated in a post to an Intel blog: "We often talk about our focus on driving innovation for the enthusiast community, a targeted but growing segment of the PC market. This point is underscored by what we have been delivering with our Intel Core X-series processors, Intel Core H-series mobile processors and, more recently, the first of our 8th Gen Intel Core desktop processors. Each product line offers a range of new capabilities, workloads and form factors to cater to the diverse needs of enthusiasts. Today, we're sharing initial details on a new product that does exactly that, reducing the usual silicon footprint to less than half that of standard discrete components on a motherboard. That's more freedom for OEMs to be creative and deliver innovative thin and light designs with improved thermal dissipation. It also delivers space to add new features, create new board layouts, explore new cooling solutions or increase battery life. The new product, which will be part of our 8th Gen Intel Core family, brings together our high-performing Intel Core H-series processor, second generation High Bandwidth Memory and a custom-to-Intel third-party discrete graphics chip from AMD's Radeon Technologies Group - all in a single processor package." The Wall Street Journal had previously reported that the two companies were teaming up in an effort to compete with Nvidia and as they hope to steal some of its share of the GPU market with a single integrated chip. BULLISH AHEAD OF RESULTS: In a research note to investors this morning, Morgan Stanley's Moore raised his price target on Nvidia to $210 from $168 ahead of the company's earnings report on Thursday. The analyst raised his estimates based on expectations for stronger cryptocurrency revenues, stronger Nintendo (NTDOY) builds, and stronger gaming results than his prior expectations. However, Moore, who still expects cryptocurrency declines from here and believes the stock seems fully valued, reiterated an Equal Weight rating on Nvidia shares. Over the weekend, Oppenheimer analyst Rick Schafer said he sees upside to consensus estimates for Nvidia, driven by continued data center and gaming momentum. Additionally, the analyst argued that cryptocurrency should provide a lift to third quarter results, but expects management to continue to take a conservative tone when forecasting this volatile vertical. Competitively, Schafer does not see any material pressure from AMD's Radeon Instinct server accelerators, or high-end Vega PC GPUs. The analyst reiterated an Perform rating on Nvidia shares, noting expectations are running high. PRICE ACTION: In morning trading, Intel has gained fractionally to $46.15 and AMD has advanced about 5% to $11.70. Meanwhile, Nvidia is flat at $208.64.

11:12 EDT Senator Harris investigating Alkermes over opioid treatment sales efforts - Senator Kamala Harris, a member of the Senate Homeland Security and Governmental Affairs Committee, has launched an investigation into Alkermes regarding its "efforts to artificially boost sales" of Vivitrol, a treatment drug for opioid addiction. "Recent reports have revealed that Alkermes attempted to increase sales of its own product while contributing to misconceptions about other medications used in the fight to combat the opioid epidemic, and worked to limit their availability," the Senator writes in a press release. She is requesting information from Alkermes including marketing materials, financial transactions, internal reports, and detailed records. Her statement adds, "For the last several years, Alkermes aggressively marketed its drug to people in the criminal justice system, often convincing judges and corrections officials to offer Vivitrol to inmates and parolees rather than treatment drugs with more proven efficacy. Alkermes officials have also spent hundreds of thousands of dollars lobbying state and federal lawmakers and officials in order to receive favorable promotion of Vivtrol and federal funding." Alkermes in morning trading is down 2% to $50.12. Reference Link

11:08 EDT Tivity Health sinks 18%, or $8.60, to $39.45

10:54 EDT Mylan says EpiPen expected to be less than 3% of total sales

10:46 EDT Mylan CEO: Demand for high-quality generics 'will not be going away' - Mylan CEO Heather Bresch, speaking on the company's Q3 earnings conference call, said the company's plant in Puerto Rico is "operational" and Mylan has not seen shortages from the drugs the company makes at that facility. Commenting on the FDA approval for generic Compaxone, Bresch said that "after years of hopeful anticipation, it finally happened." She said the demand for high-quality generics "will not be going away." Bresch noted the company's "depressed" share price, which she said is "reflective of investor sentiment regarding a U.S.-only marketplace." She said the key message is that Mylan is "built to last, and that what makes us different is what makes us durable." "We see a strong finish ahead," Bresch said. Mylan is up about 0.7% to $35.97 in morning trading.

10:30 EDT CVS announces nationwide next-day delivery in select markets - CVS Pharmacy announced plans to bring prescriptions directly to patients' doors with nationwide next-day delivery from CVS Pharmacy locations beginning in early 2018. Select cities will also offer same-day delivery within hours, allowing customers to keep all of their pharmacy needs with a trusted pharmacy partner while also having the option of getting their prescriptions delivered right to their door. "Our goal is to meet the needs of our all of our customers wherever, however and whenever they want," said Helena Foulkes, EVP, CVS Health and President, CVS Pharmacy. "Providing same and next-day options for delivery of medications is just another way we can help our patients get and stay healthy." CVS Pharmacy will offer free, same-day delivery service within hours from all locations in Manhattan beginning on December 4. Prescriptions and a curated selection of over-the-counter products will be delivered directly from CVS Pharmacy in secure tamper-proof packaging right to customers' doors to assure complete privacy. Same-day delivery will expand to Miami, Boston, Philadelphia, Washington, DC and San Francisco in early 2018. CVS Pharmacy also continues to expand its partnership with Instacart to offer personal shopping at 2,600 CVS Pharmacy stores across the country for delivery of front store products, including healthy food choices, beauty products and over-the-counter medications, with plans to expand the service to reach 50 percent of U.S. households by year end. CVS Curbside, which allows customers to shop online or via the CVS app for pick up in the store in an hour, without ever leaving their car, is active in locations coast-to-coast.

10:17 EDT Sysco says 'confident' in ability to achieve three-year plan objectives - Says Q1 operating income would be $10M higher if not for impact of hurricanes. Says continues to execute customer-centric strategy at high level. Says continually improving implementation of commercial, supply chain and cost reduction strategic initiatives. Says prospects of international business compelling, sees significant potential for international business over next few years. Says continues to invest in Sysco brand and reinvigorate portfolio. Says managing overall cost structure remains key priority. Says acquiring HFM provides direct access to growing Hawaiian market. Says European business is facing macroeconomic headwinds, expects headwinds to continue through FY18. Comments taken from Q1 earnings conference call.

10:10 EDT Majesco trading halted, volatility trading pause

09:56 EDT Michael Kors' beat and raise boosts shares of luxury retailers - Shares of Michael Kors (KORS) jumped in early trading after the apparel and accessories maker gave better than expected guidance for the fiscal year after announcing top and bottom line results for its most recent quarter that topped consensus forecasts. EARNINGS BEAT: Michael Kors reported second quarter earnings per share of $1.33 on revenue of $1.15B, handily beating analysts' consensus estimates of 83c and $1.04B, respectively. Second quarter comparable store sales decreased 2.5%, a smaller decline than the 4.7% drop analysts were expecting. The company's earnings also beat previous guidance calling for EPS of 80c-84c on revenue of $1.035B-$1.055B and comp sales down in the mid-single digits range. Retail net sales for the quarter increased 8% to $645M, while wholesale net sales were up 2.5% to $263.6M on a constant currency basis. Licensing revenue fell 2.1% to $38M. Looking ahead, Michael Kors raised its fiscal 2018 forecast and now sees EPS of $3.85-$3.95 on revenue of about $4.59B, against analysts' estimates of $3.71 and $4.3B, respectively. Comparable sales for the Michael Kors brand are expected to decline in the mid-single digits. In its last earnings report, Michael Kors forecast EPS of $3.62-$3.72 on revenue of $4.275B and SSS down in the mid-single digits. Third quarter earnings per share, however, is expected to be $1.22-$1.27, well below analysts' estimates of $1.50, but includes anticipated dilution from Jimmy Choo of about 4c. Revenue is seen at $1.355B-$1.385B, including $105M-$110M of incremental Jimmy Choo revenue, above estimates of $1.29B. Comparable sales for the Michael Kors brand are expected to decline in the high-single digits. TRANSITION YEAR: Michael Kors Chairman and Chief Executive Officer John Idol said in a statement that "Our second quarter results were better than expected, and we are pleased with our continued progress executing on our strategic plan, Runway 2020." Idol, who reiterated that FY18 will be a "transition year" for the Michael Kors brand, said its efforts will ultimately drive improved financial performance. On its earnings conference call, Idol reiterated that he believes Jimmy Choo can reach $1B in sales over time. Additionally, Idol revealed a 360-degree marketing campaign with Google (GOOG, GOOGL) to support Access smartwatches "to further heighten demand." Idol said the fashion watch category is "challenging" and sees continued sales declines for the year in the total watch category. The company expects to close 40-50 stores in the fiscal year, more than its previous view of 20-40 stores. Kors previously announced plans to close 100-125 of its full-price retail stores over the next two years. ANALYST COMMENTARY: Buckingham maintained its Neutral rating on Michael Kors and noted that Q3 guidance calls for "significant" deceleration and margin pressure. The firm said the Kors brand still has a loyal consumer base, albeit smaller than at its peak, that will pay full price for the brand, but that overall growth will be "a challenge." The firm remains on the sidelines despite an "attractive" valuation, but would look to become more constructive when it is more confident that sales and margins represent "trough" levels. Oppenheimer noted Kors' "strong" quarter, and said the stock would be up more if not for the lower Q3 guidance. PRICE ACTION: Shares of Michael Kors are up about 15% in early trading to $54.70. Shares are up nearly 28% year-to-date. OTHERS TO WATCH: Others in the luxury accessory space trading higher include Vera Bradley (VRA), up 3%, and Coach, which recently changed its name to Tapestry (TPR), up 1%.

09:50 EDT Liberty Expedia Holdings (Series B) trading resumes

09:42 EDT Premier announces multi-year agreement with OU Medical Center - OU Medical Center has signed a multi-year agreement with Premier to access performance improvement technology solutions and services that support advances in highly reliable care, the company announced. In expanding its partnership with Premier, OU Medical Center has joined the QUEST 2020 quality improvement collaborative, the company noted. The financial terms of the agreement were not disclosed. The partnership is not expected to materially impact Premier's fiscal 2018 financial results, Premier added.

09:37 EDT Dragon Victory enters strategic cooperation agreement for crowdfunding upgrade - Dragon Victory International announced that the company has entered into a Strategic Cooperation Agreement with Jiawei Cao, who is experienced in the auto parts and insurance industry with a wealth of related resources in China, for crowdfunding platform upgrade. The Agreement, dated as of November 3, is intended to strengthen the objective and growth of LYL as an innovative business service provider and complement the current platform with an additional transaction model that generates rewards for users and customers. LYL's current platform will be upgraded to set-up a business ecosystem enabling customers of internet auto-insurance to take full advantage of the full range of off-line services provided by auto service providers. The new component of the LYL platform allows car owners to buy auto insurance on LYL's platform and in return, receive rewards vouchers eligible for auto services to be provided by partner auto service providers. Currently, more than 450 auto service providers have signed up to join LYL's program. The management of LYL expects that over 20,000 auto service providers will join the program by the end of 2018, which is expected to create RMB0.72B revenue for HDATS. Pursuant to the Agreement, LYL and Jiawei Cao will form a joint venture in China, namely, Hangzhou Dacheng Automotive Technology Service. The registered capital of HDATS will be RMB16.66M, of which RMB3M will be contributed by LYL and RMB1M will be contributed by Jiawei Cao within one week following execution of the Agreement, with the remaining capital payments to be made in installments over the next few years. In return, LYL and Mr. Cao will each own 60% and 40% of the equity interest of HDATS, respectively. LYL will be leading HDATS's financing efforts for its business expansion and Mr. Jiawei Cao will cooperate with LYL to operate and manage HDATS. This cooperation includes many business initiatives, such as R&D of auto parts, auto refurbish, auto repair, auto supply and related consulting services. HDATS will share LYL's significant online user base and Jiawei Cao's related resources to explore business opportunities in China.

09:23 EDT Amedica submits 510(k) application for Valeo C+CSC with Lumen spinal implant - Amedica announced that the company made a 510(k) submission to the FDA for its Valeo C+CSC with Lumen spinal implant. The Valeo C+CSC with Lumen is a modified CSC that is similar to Amedica's commercially available Valeo C and Valeo C+ CSC cervical implants. This device increases implant surface area and plays an active role in the spinal fusion process while maintaining the other benefits silicon nitride brings to patients and physicians.

09:19 EDT On The Fly: Pre-market Movers - UP AFTER EARNINGS: CVS Health (CVS), up 1%... Heron Therapeutics (HRTX), up 1.3%... Flex Pharma (FLKS), up 8.4%... Mylan (MYL), up 1.6%. ALSO HIGHER: Qualcomm (QCOM), up 5% after confirming an unsolicited proposal from Broadcom (AVGO) to acquire the company for $70 per share. Broadcom is up 2.3%. DOWN AFTER EARNINGS: Anthera (ANTH), down 5.6%... TC Pipelines (TCP), down 1.96%. ALSO LOWER: Sprint (S) is down 12% and T-Mobile (TMUS) is down 5.6% after the Wall Street Journal reported the companies ended their merger negotiations.

09:10 EDT Orbotech sees FY20 revenues $1.25B - Orbotech unveiled a new mid-term financial model at the Company's Investor Day in New York. Orbotech's model targets revenues exceeding $1.25B by 2020, resulting from organic growth opportunities driven by electronics megatrends such as connectivity, automotive, artificial intelligence, augmented reality and virtual reality. Under the 2020 financial model, revenues are planned to exceed $1.25B by 2020, with gross margins of 50%, research and development investment of 12%-14%, adjusted EBITDA margin of 27%-29% and non-GAAP net income margin of 21%-23%.

09:08 EDT CVS Health sees FY17 Retail/LTC SSS down 2.75%-3.25% - Sees FY17 Retail/LTC net revenue down 2.25%-2.75%; Same-store adjusted scripts flat to 0.25%.

09:05 EDT CVS Health says sees Q4 Retail/LTC SSS down 1%-2.75% - Sees Q4 Retail/LTC net revenue down 0.5%-2.25%.

09:03 EDT Arthur J. Gallagher acquires Allied Business Network for undisclosed amount - Arthur J. Gallagher & Co. announced the acquisition of Pittsburgh, Pennsylvania-based Allied Business Network, or ABN, and Smart Business Savings, or SBS. Terms of the transaction were not disclosed.

09:02 EDT Citi expands Payer ID to 17 new markets - Citi's Treasury and Trade Solutions has expanded its Citi Payer ID offering to 17 new markets across North America and Western Europe, making it now available in 44 countries. Designed as a best-in-class receivables reconciliation solution, Citi Payer ID allows institutional clients manage their working capital with greater efficiency by providing the following benefits: Increased visibility into incoming payments for effective payer reconciliation, reduced days sales outstanding, and improved order-to-cash cycle for increased working capital efficiencies and enhanced automation and cost savings, along with reduced exceptions.

09:01 EDT Exxon Mobil partners with Singapore universities to open energy center - ExxonMobil announced that it is partnering with two Singapore universities to open a Singapore Energy Center in 2019 to focus on new discoveries and significant improvements to technologies that could improve energy production, and enhance energy efficiency and other efforts to mitigate the risk of climate change. ExxonMobil signed a memorandum of understanding with the Nanyang Technological University and the National University of Singapore to become a founding member of the proposed center - the company's first such research and development partnership outside the United States. As a founding member, ExxonMobil will support the center's wide range of early-stage research projects. Company researchers and scientists will also collaborate with students and faculty at the two universities, as well as other industry contributors, once the center opens in early 2019.

08:56 EDT Michael Kors: Fashion watch category challenging, sees continued sales declines - Michael Kors (KORS) CEO John Idol reiterated on the company's Q2 earnings conference call that that he believes Jimmy Choo can reach $1B in sales over time. Idol said Kors plans to increase new accessories by 50% for the holiday season. Idol said Kors has a 360-degree marketing campaign with Google (GOOG) to support Access smartwatches to further heighten demand for the smartwatches. Idol said Kors saw a double digit increase in comp sales for digital flagships in Q2; he noted 40% fewer days on promotion, which negatively impacted comp sales, but benefited from increased AURs. Idol also noted that Hong Kong, Macau continued to be challenged, but started to see signs of improvement in Q2. Idol said the fashion watch category is "challenging" and sees continued sales declines for FY in the total watch category. Idol still sees FY18 as a "transition year" for the Michael Kors brand. Comments taken from the Q3 earnings conference call. Michael Kors is up 6.15% in premarket trading.

08:50 EDT CVS Health says expects to return more than $7B to shareholders in 2017 - Through dividends and share repurchases.

08:47 EDT Cemtrex to acquire virtual reality software development studio in New York City - Cemtrex signed a letter of intent to acquire a virtual reality software development studio headquartered in New York City. This virtual reality and software development studio has been in business since 2010, has a talented pool of over 30 programmers with experience in prototype development & interaction design with annual sales of over $1.5M. The studio's Augmented Reality, or AR, and Virtual Reality, or VR, software and solutions help its clients develop software for training simulations, building product prototypes, creating virtual customer experiences and gaming apps. The software studio also has widespread web, iOS, Android, and Windows software development capabilities. Due to the confidentiality agreement in place, the company will provide details about the acquired company after closing the transaction. The company expects to close this transaction by end of the year and the terms of the deal have not been announced.

08:44 EDT CVS Health says overall growth in Specialty Pharma 'remains strong' - Says specialty business continues to expand and gain share.

08:42 EDT UroGen Pharma announces first patient enrolled in Allergan RTGel/Botox trial - UroGen Pharma (URGN) announced the enrollment of the first patient in a Phase 2 clinical trial of RTGel in combination with Botox for the treatment of overactive bladder. The Phase 2 trial is being conducted by Allergan Pharmaceuticals (AGN) International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, under the terms of a license agreement with UroGen Pharma. RTGel is UroGen Pharma's proprietary sustained release, hydrogel-based formulation technology designed to enable longer exposure of the urinary tract tissue to active pharmaceutical ingredients with which it may be combined, including Botox. Botox injection into the bladder is approved as a pharmacologic therapy for the treatment of overactive bladder.

08:39 EDT CVS Health estimates impact from hurricanes approximately $55M - Costs primarily in Retail/LTC to cover insurance deductibles. Says 11 stores remain closed, about 925 stores were closed for some period of time. Comments from Q3 earnings conference call.

08:38 EDT VistaGen Therapeutics receives EU patent for AV-101 - VistaGen Therapeutics announced that the European Patent Office, or EPO, granted a European Patent for AV-101, the company's oral CNS drug candidate in Phase 2 development for major depressive disorder, or MDD. The patent relates to the treatment of depression, Parkinson's disease levodopa-induced dyskinesia, or PD LID, and use of multiple dosage forms to treat these CNS disorders. The patent has been validated in Belgium, Denmark, France, Germany, Ireland, Italy, Portugal, Spain, Switzerland and the United Kingdom. It will be in effect until January 2034.

08:36 EDT Heron Therapeutics backs FY17 Sustol sales guidance $25M-$30M - Net product sales of SUSTOL extended-release injection for the three and nine months ended September 30, 2017 were $8.6M and $20.7M respectively. Heron commenced commercial sales of SUSTOL in October 2016. Guidance for full-year 2017 net product sales of SUSTOL remains $25M to $30M.

08:34 EDT Hailiang Education Group appoints Jianguo Yu as CFO - Hailiang Education Group announced the appointment of Jianguo Yu as its new CFO, succeeding Hancheng Lee, effective November 3. Lee will remain available and work in the Company's finance department to assist the new CFO during the transition. Jianguo Yu, who is a licensed California Certified Public Accountant and a Certified International Certified Internal Auditor, has over 20 years of successful track record in audit and management in the U.S., and is especially proficient in Generally Accepted Accounting Principles.

08:32 EDT Aimmune CEO Stephen Dilly to retire by end of 2018 - Aimmune announced that CEO Stephen Dilly, M.B.B.S., Ph.D., plans to retire by the end of 2018. Aimmune will initiate a search for a successor CEO to lead the company as it builds towards the potential commercial launch of its lead investigational product, AR101, which is currently in Phase 3 development for the treatment of peanut allergy. Dilly will continue as Aimmune's CEO until his replacement joins the company and will be available through a transition period. "My decision to retire is based solely on my personal desire to have more time for my family, especially my eldest son, who has special needs," said Dilly. "We are announcing this now in order to facilitate an orderly executive search and transition period, and I remain completely committed to continuing to lead Aimmune through the exciting events ahead. We are looking forward to the completion of our pivotal Phase 3 PALISADE trial around year-end and sharing top-line data in the first quarter of 2018."

08:31 EDT Aimmune says CEO Stephen Dilly to retire by end of 2018 - Aimmune announced that CEO Stephen Dilly, M.B.B.S., Ph.D., plans to retire by the end of 2018. Aimmune will initiate a search for a successor CEO to lead the company as it builds towards the potential commercial launch of its lead investigational product, AR101, which is currently in Phase 3 development for the treatment of peanut allergy. Dr. Dilly will continue as Aimmune's CEO until his replacement joins the company and will be available through a transition period.

08:16 EDT Pareteum awarded $1M contract - Pareteum announced that it has been awarded a 3-year contract, scheduled to add approximately $1M to the Company's $114M 36-month contractual revenue backlog, by a digital brand management communications company. Pareteum's Global Mobility Cloud Platform delivers instant messaging services that connect wireless subscribers to receive and send messages anytime from anywhere. This breakthrough is a step toward independence from being tied solely to one network. Under the terms of the agreement, Pareteum receives a fee for every connection that is made between the brand and its mobile subscribers who have elected to receive messages and notifications directly to their phone.

08:10 EDT CPI Aerostructures awarded $15.8M contract by Lockheed Martin - CPI Aerostructures (CVU) announced that it has been awarded a $15.8M multi-year contract by Lockheed Martin (LMT) to manufacture canopy actuation drive shaft assemblies for the F-35 Lightning II, the world's most advanced multirole fighter. Under this new contract with Lockheed Martin's Aeronautics division based in Fort Worth, TX, CPI Aero will provide four different drive shaft assemblies used within the actuation system that opens and closes the cockpit canopy of all three variants of the aircraft: the F-35A conventional takeoff and landing, or CTOL, variant, the F-35B short takeoff/vertical landing, or STOVL, variant, and the F-35C carrier variant, or CV. Deliveries are expected to begin during the third quarter of 2018 and continue through December 31, 2022. This is CPI Aero's second contract with Lockheed Martin for structural assemblies on the F-35. In May 2017, CPI Aero made its first delivery of lock assemblies for the arresting gear door of the F-35A CTOL variant under a multi-year contract awarded in 2015 estimated at up to $10.6M.

08:06 EDT Natera announces research collaboration with Denmark's Aarhus University - Natera announced a second research collaboration with Denmark's Aarhus University utilizing the company's Signatera technology to evaluate ctDNA as a useful biomarker for detecting minimal residual disease, treatment response, and disease recurrence in colorectal cancer patients. The company previously announced that the university would be using the Signatera technology in a bladder cancer study. This second study will evaluate 130 patients with stage I-III colorectal cancer previously treated with surgery and adjuvant chemotherapy, and then monitored longitudinally with blood samples drawn approximately every three months for up to 36 months. Sequencing data from each individual's tumor will be provided by Aarhus University and analyzed using the Signatera proprietary bioinformatics pipeline, resulting in custom ctDNA assays designed for each individual. The objective of the study is to determine the relationship between post-surgical ctDNA levels, minimal residual disease, disease relapse, and adjuvant therapeutic response. Study results are expected in 2018, which will help support the launch of Signatera in the clinical setting.

08:05 EDT Buenaventura reports resumption of operations at Uchucchacua mine - Buenaventura announced that Buenaventura's Uchucchacua mine has resumed operations. As was previously reported, a task force was established on November 3, 2017 by the Office of Social Affairs of the Ministry of Energy and Mines with the participation of other public offices, including representatives from the Prime Minister's office, in order to end the conflict to resume negotiations. The Oyon community has therefore honored its commitment to remove its roadblock, which was preventing Buenaventura's team from entering the Uchucchacua Mine site. Normal operations at Uchucchacua resumed on November 4.

08:05 EDT Choice Hotels sees FY17 adjusted EPS $2.84-$2.88, consensus $2.85 - Sees FY17 adjusted EBITDA $294M-$298M; adjusted EBITDA from hotel franchising activities $301M-$305M; net domestic unit growth 2.5%-3%; RevPAR is expected to increase between 2%-3%. Net reductions in FY17 adjusted EBITDA, relating to the company's non-hotel franchising operations are expected to be approximately $7M.

08:03 EDT Intersect ENT says FDA performs preapproval inspection of Menlo Park facility - Intersect ENT announced that the U.S. FDA has performed a Pre-Approval Inspection of the company's Menlo Park facility related to the company's New Drug Application (NDA) for the investigational SINUVA Steroid Releasing Sinus Implant. At the conclusion of the inspection, the FDA issued a Form 483 with four inspectional observations. "We appreciate the FDA's close review and are committed to fully addressing the agency's observations within the 15-day response timeframe," said Lisa Earnhardt, president and CEO, Intersect ENT. "We are excited to have completed another important milestone as we continue to advance SINUVA through the NDA process." The FDA has set a PDUFA target action date of January 7, 2018. The company does not expect these observations to impact the timeline for a decision from the FDA on approval of the SINUVA implant.

07:46 EDT xG Technology announces $343.000 order - xG Technology announced that its IMT Vislink business has received a $343,000 order from a leading robotic defense contractor for wireless video transmission modules for use in military remote ordnance disposal applications.

07:43 EDT Avinger enters into common stock purchase agreement for up to $15M - Avinger announced that it has entered into a $15M common stock purchase agreement with Lincoln Park Capital Fund, a Chicago-based institutional investor. The company is filing a registration statement with the SEC relating to the transaction, and upon its effectiveness, Avinger will have the right and the sole discretion to sell to LPC up to $15M worth of shares over a 30-month period subject to certain limitations. Avinger will control the timing and amount of any future investment, and LPC will be obligated to make purchases in accordance with the Purchase Agreement. Proceeds from sales of common stock pursuant to the agreement will be used for working capital and general corporate purposes.

07:37 EDT Aehr Test Systems announces order for ABTS from new customer in China - Aehr Test Systems announced that it has received an order for its Advanced Burn-in and Test System, or ABTS, from a new customer in China. This system is expected to ship in Aehr Test's Q4.

07:32 EDT Jones Lang LaSalle declares dividend of 37c per share - The dividend will be paid on December 15 to shareholders of record at the close of business on November 16.

07:24 EDT Richmont Mines and Alamos Gold shareholders recommended to vote FOR - Alamos Gold (AGI) and Richmont Mines (RIC) announced that Institutional Shareholder Services and Glass, Lewis & Co. two leading proxy advisory firms, have recommended that both Alamos and Richmont shareholders vote FOR the plan of arrangement whereby Alamos will acquire all of the issued and outstanding shares of Richmont, at their special meetings of shareholders to be held on November 16.

07:20 EDT Qualcomm trading resumes

07:19 EDT Franco-Nevada reports 123,787 Gold Equivalent Ounces sold in Q3 -

07:15 EDT Baker Hughes announces $3B share repurchase authorization - Baker Hughes (BHGE), a GE (GE) company, announced that its Board of Directors has authorized Baker Hughes, a GE company, LLC to repurchase up to $3B of its common units from BHGE and GE. The company will use the proceeds from the sale of its BHGE LLC common units to repurchase its Class A shares. In addition, the company also announced its intention for BHGE LLC to issue new debt. BHGE and BHGE LLC have also entered into an agreement with GE whereby BHGE LLC will repurchase its common units from GE on a pro rata basis and on the same terms as it repurchases common units from BHGE. The proceeds distributed to BHGE will be used to repurchase Class A shares on the open market or in privately negotiated transactions. The repurchases will not materially change BHGE and GE's relative economic interests in BHGE LLC or BHGE's Class A and Class B stockholders' relative voting interest.

07:13 EDT Neovasc receives FDA approval to initiate pivotal reducer trial - Neovasc announced that it has received approval of the U.S.FDA to initiate the COSIRA-II IDE pivotal clinical trial. The trial's purpose will be to demonstrate the safety and effectiveness of the company's novel Reducer system for treatment of patients with refractory angina. Once completed, the trial data is intended to support an application to the FDA for approval to begin marketing Reducer in the United States.

07:10 EDT VBL Therapeutics sign exclusive agreement for VB-111 in Japan - VBL Therapeutics announces an exclusive license agreement with NanoCarrier for the development, commercialization, and supply of ofranergene obadenovec, or VB-111, in Japan. VBL Therapeutics retains rights to VB-111 in the rest of the world. Under terms of the agreement, VBLT has granted NanoCarrier an exclusive license to develop and commercialize VB-111 in Japan for all indications, VBLT will supply NanoCarrier with VB-111, and NanoCarrier will be responsible for all regulatory and other clinical activities necessary for commercialization in Japan. In exchange, VBLT receives an up-front payment of $15M, and is entitled to receive greater than $100M in development and commercial milestone payments. VBLT will also receive tiered royalties on net sales in the high-teens. Other terms of the agreement are not being disclosed. In addition to this agreement, VBL Therapeutics and NanoCarrier intend to explore future collaborations in oncology.

07:08 EDT Broadcom proposes to acquire Qualcomm for $70 per share in cash and stock - Broadcom Limited (AVGO) announced a proposal to acquire all of the outstanding shares of Qualcomm (QCOM) for per share consideration of $70.00 in cash and stock. Under Broadcom's proposal, the $70.00 per share to be received by Qualcomm stockholders would consist of $60.00 in cash and $10.00 per share in Broadcom shares. The Broadcom proposal stands whether Qualcomm's pending acquisition of NXP Semiconductors (NXPI) is consummated on the currently disclosed terms of $110 per NXP share or the transaction is terminated. The proposed transaction is valued at approximately $130B on a pro forma basis, including $25B of net debt, giving effect to Qualcomm's pending acquisition of NXP on its currently disclosed terms. Broadcom's proposal was unanimously approved by its board. Broadcom said it is "prepared to engage immediately in discussions with Qualcomm to work toward a mutually acceptable definitive agreement and is ready to devote all necessary resources to finalize the necessary documentation on an expeditious basis." The proposed transaction will not be subject to any financing condition. BofA Merrill Lynch, Citi, Deutsche Bank, J.P. Morgan and Morgan Stanley have advised Broadcom in writing that they are "highly confident that they will be able to arrange the necessary debt financing for the proposed transaction." Silver Lake Partners, which has served as a strategic partner to Broadcom in prior transactions, has provided Broadcom with a commitment letter for a $5B convertible debt financing in connection with the transaction. Broadcom expects that the proposed transaction would be completed within approximately 12 months following the signing of a definitive agreement.

07:08 EDT Flex Pharma reports 'positive' topline data form Phase 2 trial of FLX-787 - Flex Pharma announced positive topline data for FLX-787 from its randomized, double-blinded, placebo-controlled, cross-over Australian trial in ALS patients with frequent muscle cramps. The study was terminated early to focus the company's resources on the ongoing US Phase 2b ALS study. In eight patients who completed the trial per protocol, FLX-787 demonstrated a statistically significant percentage reduction from baseline in both cramp-associated pain intensity and stiffness, relative to placebo control, based on daily patient assessments by Numerical Rating Scale. Strong and consistent trends were demonstrated on multiple endpoints, including: percentage reduction in the number of cramps from baseline, increase in cramp free days from baseline, and improvements on both the Patient and Clinician Global Impression of Change. FLX-787 was generally well tolerated. In the patients completing both cross-over periods per protocol: FLX-787 showed a median 31% reduction in cramps from baseline versus 0.1% reduction for patients while on placebo control; Patients had a median of 4.4 cramp free days versus 0 for placebo control; Patients evaluated themselves as improved with FLX-787 treatment 50% of the time versus 12.5% with placebo control; and Clinicians blinded to treatments evaluated 50% of patients as improved with FLX-787 versus 0% for placebo control.The company also analyzed the Period 1 and Period 2 results of all patients randomized in the trial and believes the cross-over results are not driven by a cross-over bias or unblinding effect.

07:07 EDT Cardinal Health announces CEO succession plan, CFO Mike Kaufmann to be CEO - Cardinal Health announced that it has named Mike Kaufmann, its current CFO, to serve as the company's next CEO and join the board, effective Jan. 1, 2018. Kaufmann will succeed George Barrett, 62, Cardinal Health's chairman and CEO since 2009, who will continue to serve as executive chairman of the board through the annual meeting of shareholders in November 2018. At that time, Gregory Kenny, Cardinal Health's lead independent director, will assume the role of non-executive chairman. Additionally, as part of the succession plan, Jorge Gomez will succeed Mike Kaufmann as Cardinal Health's CFO. Gomez currently serves as senior vice president and CFO of Cardinal Health's Medical segment and previously served as chief financial officer of Cardinal Health's Pharmaceutical segment, as well as in roles as both the company's treasurer and controller.

07:05 EDT Broadcom proposes to acquire Qualcomm for $70 per share

07:05 EDT SilverBow Resources names Steven Adam as COO, succeeding Robert Banks - SilverBow Resources announced the appointment of Steven W. Adam as EVP and COO, effective November 6, 2017 and is succeeding Robert J. Banks who is separating from the company to pursue other endeavors.

07:04 EDT Alpine Immune presents data demonstrating preclinical activity in arthritis - Alpine Immune Sciences announced results from preclinical studies evaluating ALPN-101 program dual ICOS/CD28 antagonists generated by the company's variant immunoglobulin domain platform. The ICOSL vIgD-Fc fusion proteins demonstrated potent activity in an animal model of inflammatory arthritis and in a humanized model of graft vs. host disease. Findings suggest molecules from the company's vIgD platform could potentially have clinical therapeutic utility in multiple inflammatory diseases. The data were presented today in a poster session titled "Rheumatoid Arthritis - Animal Models Poster II" at the 2017 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting in San Diego, CA. Presented data from the ICOSL vIgD-Fcs: Inhibited multiple parameters of disease in inflammatory arthritis including reducing paw swelling, inflammatory cell infiltrates, circulating inflammatory cytokines, anti-collagen autoantibodies, and lymph node follicular helper T cells, B cells, and activated T cells. Prolonged survival and reduced disease activity in GvHD. Appeared superior to abatacept in arthritis based on clinical scores and histology, and to belatacept in GvHD based on disease activity scores and survival.

07:03 EDT Wave Life Sciences initiates trial for lead program in DMD - Wave Life Sciences announced the initiation of a global Phase 1 clinical trial for WVE-210201 in Duchenne muscular dystrophy patients amenable to exon 51 skipping. This clinical trial marks the next stage in the company's ongoing commitment to address the significant unmet needs of patients diagnosed with this devastating disease and it is the company's third clinical trial initiated in 2017. The Phase 1 study is a multicenter, double-blind, placebo-controlled clinical trial designed to evaluate the safety, tolerability and plasma concentrations of single ascending doses of WVE-210201 administered intravenously in DMD patients with gene mutations amenable to exon 51 skipping. Data from the Phase 1 trial for WVE-210201 are expected in Q3 2018 and will facilitate the rapid transition to a double-blind, placebo-controlled, multi-dose efficacy study where dystrophin expression and clinical outcomes will be assessed. The clinical program is designed to allow patient participants in the Phase 1 trial to enroll in an open-label extension study in which dosing with WVE-210201 will continue. The open-label extension study and the planned efficacy study are each intended to follow the Phase 1 trial and expected to include an interim efficacy readout of dystrophin expression from muscle biopsies in 2H 2019. Wave's first global clinical trial in DMD is expected to enroll up to 40 patients between the ages of 5 and 18 years. The Phase 1 inclusion criteria allow for participation of both ambulatory and non-ambulatory patients, including those previously treated with eteplirsen following an appropriate washout period. The trial has been initiated in the United States, with Europe and other regions to follow. Intravenous doses tested in the Phase 1 trial will escalate through a range expected to be clinically relevant. In the U.S., Wave is required to provide data from ongoing preclinical studies to the FDA in order to progress to the highest dose cohorts and planned multi-dose studies. Inaddition to its exon 51 program, Wave is leveraging its stereopure chemistry platform to advance investigational therapies targeting additional DMD-related exons. In September 2017, Wave announced that its next DMD development program will target exon 53 and is expected to initiate clinical trials in Q1 2019. In addition, the company is exploring both intravenous and subcutaneous administration for the WVE-210201 and exon 53 programs.

07:01 EDT Bristol-Myers Opdivo demonstrates superir 3-year survival for patients with RCC - Bristol-Myers Squibb announced a three-year overall survival update from its phase 3 CheckMate -025 study, evaluating patients treated with Opdivo versus everolimus in previously treated advanced renal cell carcinoma - RCC. These data are the first of any anti-PD-1 agent to demonstrate durable survival at three years in previously treated RCC. No new safety signals were identified and the data showed a safety profile consistent with two-year results. The median OS, the primary endpoint in this study, for Opdivo was 25.8 months compared to 19.7 months with everolimus. The three-year OS rate was 39% for Opdivo and 30% for everolimus. The safety profile of Opdivo was consistent with that of previous reports.

06:59 EDT Qualcomm trading halted, news pending

06:57 EDT Michael Kors reports Q2 comparable sales decreased 2.5% - Retail net sales increased 8.0% to $645.0 million driven in large part by 56 net new store openings since the end of the second quarter of fiscal 2017, as well as the increase in ecommerce sales in Europe and Asia. Comparable sales decreased 1.8%. On a constant currency basis, retail net sales increased 7.2%, and comparable sales decreased 2.5%. Wholesale net sales increased 2.5% to $463.6 million and on a constant currency basis, wholesale net sales increased 1.2%. Licensing revenue decreased 2.1% to $38.0 million.

06:53 EDT Leidos awarded prime contract award from Naval Health Research Center - Leidos was awarded a prime contract by the Naval Health Research Center, or NHRC, to continue to provide research and development support services to the Warfighter Performance department. The single-award cost-plus-fixed fee follow-on contract has a ten-month base period of performance, four one-year options, and a total contract ceiling of approximately $29M if all options are exercised. Work will be performed primarily in San Diego, CA.

06:50 EDT PUR selects Brandgenuity to drive licensing efforts - PUR has selected Brandgenuity to serve as its licensing agency in North America. The agency will extend the brand and leverage its reputation for quality and innovation into new and exciting product categories. PUR is marketed by the Health and Home division of Helen of Troy.

06:41 EDT TherapeuticsMD can submit NDA for TX-004HR without pre-approval study - TherapeuticsMD announced a regulatory update regarding the New Drug Application for TX-004HR, the company's investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse, a symptom of vulvar and vaginal atrophy due to menopause. On November 3, the company participated in an in-person meeting with the Division of Bone, Reproductive, and Urologic Products of the FDA. At the meeting, the division agreed to the resubmission of the NDA for TX-004HR without the need for an additional pre-approval study. The company will commit to conduct a post-approval observational study. TherapeuticsMD believes it will be in a position to resubmit the NDA for TX-004HR within the coming weeks, with a potential approval of the NDA within two to six months after resubmission, depending on the classification of the review of the NDA. "We appreciate the hard work and collaborative effort by the FDA in moving TX-004HR one step closer to approval," said TherapeuticsMD CEO Robert Finizio. "We are extremely pleased with the FDA's position that an additional pre-approval safety study is no longer necessary for the resubmission of the NDA for TX-004HR." Shares of TherapeuticsMD are up 49%, or $2.15, to $6.51 in premarket trading.

06:36 EDT Keysight Technologies reaffirms Q4 guidance - Keysight Technologies will release Q4 earnings after the stock market closes on Wednesday, Dec. 6.

06:34 EDT Stewart announces review of strategic alternatives - Stewart announced that the board has previously formed a strategic committee which has been pursuing the full range of strategic alternatives available to Stewart. These alternatives include, among other things, business combinations, the sale of the company, and continuing to execute on Stewart's standalone business plan. The company has retained and will be assisted in the strategic review process by Citi as financial advisor and Davis Polk & Wardwell LLP as legal advisor. The board plans to complete this process in an expeditious manner. There can be no assurance that this process will result in a particular outcome. The company does not intend to provide updates on its review until it deems further disclosure is appropriate or required.

06:31 EDT SAIC awarded $980M task order by GSA - The General Services Administration, GSA, on behalf of the U.S. Army Software Engineering Directorate, awarded Science Applications International the Battlefield Systems task order worth approximately $980M. Awarded under the GSA One Acquisition Solution for Integrated Services, or OASIS, contract vehicle, the task order has a one-year period of performance, two one-year options, and work will be performed at the Army's SED in Redstone Arsenal, Alabama. Under the contract, SAIC will help field new technologies to warfighters in the field and provide systems engineering and computer resource engineering services to SED, the Aviation and Missile Research, Development, and Engineering Center (AMRDEC), and the Army Research, Development and Engineering Command, or USA RDECOM.

06:31 EDT Qatar Airways to acquire 9.6% stake in Cathay Pacific for about $661M - The Cathay Pacific board announces that on 5 November 2017, the vendors - mainly the holding company Kingboard Chemical, Kingboard Investments, a wholly-owned subsidiary of Kingboard Chemical and Kingboard Laminates - entered into the agreement with the purchaser Qatar Airways pursuant to which Kingboard Chemical, Kingboard Investment and Kingboard Laminates agreed to sell 378.2M shares in the capital of Cathay Pacificat a total consideration of HK$5,162,266,000.

06:13 EDT HFF announces sale of storage portfolio totaling 1.7M square feet - Holliday Fenoglio Fowler announces the sale of a 27-property self storage portfolio totaling 1.7M square feet and 12,171 units in Colorado, Georgia, Indiana, Kansas, Louisiana and Texas. The HFF team marketed the property on behalf of the seller, a joint venture partnership between certain funds managed by Westport Capital Partners and Store Here Management. The portfolio, which currently operates under the Store Here brand, is 80.6-percent-occupied. The properties are in eight MSAs, including Colorado Springs, Colorado; Atlanta, Georgia; Indianapolis, Indiana; Kansas City, Kansas; Shreveport, Louisiana; and Austin, Dallas and San Antonio, Texas.

06:08 EDT Achillion: FDA grants orphan drug designation to ACH-4471 - Achillion Pharmaceuticals announced that the U.S. FDA has granted orphan drug designation to ACH-4471 for the treatment of paroxysmal nocturnal hemoglobinuria. Furthermore, Achillion announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on ACH-4471 for orphan status in the European Union for the treatment of PNH.

06:01 EDT Anthem names Gail Boudreaux as CEO and President

05:39 EDT AVEO Oncology, EUSA Pharma announce tivozanib Phase 1 trial results - AVEO Oncology (AVEO) and EUSA Pharma announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib in combination with Bristol-Myers Squibb's (BMY) nivolumab, an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced renal cell carcinoma, or RCC. The results were presented on Friday, November 3, at the 16th International Kidney Cancer Symposium in Miami, in an oral presentation titled "TiNivo: A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma" by Laurence Albiges, M.D., Ph.D., Head, Genitourinary Unit, Institute Gustave Roussy, and a lead investigator of the study. The Phase 1 portion of the trial enrolled six patients, three with previously untreated metastatic RCC and three who had received first-line treatment. RCC tumor histology included five clear cell and one papillary. Tivozanib was administered to patients in two escalating dose cohorts in combination with nivolumab at a constant 240 mg every 2 weeks. The combination was well tolerated to the full dose and schedule of single agent tivozanib, with no dose limiting toxicities. The most common adverse events were hypertension, asthenia and decreased appetite. No grade 4 adverse events were reported. Two grade 3 events were reported beyond cycle 1, which did not lead to study discontinuation and were managed concurrently. Unconfirmed best response to date includes a 67% partial response, or PR, rate and a 100% disease control rate. Enrollment of approximately 20 patients in the Phase 2 portion of the trial is ongoing.

05:21 EDT Novartis announces long-term Cosentyx data - Novartis announced new long-term Cosentyx data for patients with ankylosing spondylitis, or AS. This study is unique as these data show, for the first time with any biologic, that almost 80% of AS patients treated with Cosentyx have no radiographic progression of the spine at 4 years. The new data also confirm sustained improvement in signs and symptoms in almost 80% of patients, while Cosentyx delivers a favorable and consistent safety profile. "The key finding of these data is that patients treated with Cosentyx may now have the opportunity to maintain their mobility for a longer time. This is very important as ankylosing spondylitis is a crippling condition that can impact people in their twenties when they still have many decades of their life ahead of them," said Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. "For the first time for any biologic, Cosentyx shows that almost 80% of patients had no radiographic progression for as long as 4 years. These data demonstrate the potential of Cosentyx to help patients live with less pain and retain their mobility for longer."

05:17 EDT Medtronic receives CE Mark for Intellis platform for SCS, PNS - Medtronic announced that it received CE Mark for the Intellis platform for both Spinal Cord Stimulation, or SCS, and Peripheral Nerve Stimulation, or PNS, as an aid in the management of certain types of chronic pain. Intellis, the world's smallest fully implantable SCS neurostimulator, simplifies and improves the patient experience with improved battery performance that can power the Evolve workflow, which standardizes guidance and balances high-dose and low-dose SCS therapy settings. The Intellis platform is managed on the Samsung Galaxy Tab S2 tablet interface and can record and track patient activity 24/7. Intellis is now available in Europe and the United States.